Annotation Detail
Information
- Associated Genes
- FGFR2
- Associated Variants
-
FGFR2 MUTATION
FGFR2 MUTATION - Associated Disease
- endometrial cancer
- Source Database
- CIViC Evidence
- Description
- Preclinical study in endometrial cancer cell lines (MFE-296, AN3CA, MFE-280 and Ishikawa). In cell proliferation assays, the three FGFR2 mutant cell lines were more sensitive to the pan-FGFR inhibitor ponatinib (AP24534) than the FGFR2 wild type cell line (Ishikawa) and human embryonic kidney cell line (HEK293). Ponatinib also inhibited FGFR2 kinase activity and phosphorylation (MFE-296 and MFE-280) as well as cell migration and invasion (MFE-296 and AN3CA) of FGFR2 mutated cancer cell lines.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1236
- Gene URL
- https://civic.genome.wustl.edu/links/genes/22
- Variant URL
- https://civic.genome.wustl.edu/links/variants/511
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Endometrial Cancer
- Evidence Direction
- Supports
- Drug
- Ponatinib
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 26574622
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Ponatinib | Sensitivity | true |